Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML
about
Aurora Kinase Inhibitors: Current Status and OutlookEnhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for CancerNew strategies in acute myelogenous leukemia: leukemogenesis and personalized medicine.A phase I study of danusertib (PHA-739358) in adult patients with accelerated or blastic phase chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant or intolerant to imatinib and/or other second generatA phase I study of BI 811283, an Aurora B kinase inhibitor, in patients with advanced solid tumors.Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment.Novel drugs for older patients with acute myeloid leukemia.An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia.Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?A phase 1 study of AMG 900, an orally administered pan-aurora kinase inhibitor, in adult patients with acute myeloid leukemia.Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.The Aurora kinase inhibitors in cancer research and therapy.The safety of treatment options for elderly people with acute myeloid leukemia.An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor.Emerging cell cycle inhibitors for acute myeloid leukemia.Acute Myeloid Leukemia in the Elderly Patient: New StrategiesHow has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.Lentivirus mediated silencing of ubiquitin specific peptidase 39 inhibits cell proliferation of human hepatocellular carcinoma cells in vitro.Treatment of Elderly Patients With Acute Myeloid Leukemia.A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191.Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung c
P2860
Q26770583-9131C601-7A8B-4044-94C9-8DFA62E09EF9Q29147555-B80741B3-CBD9-4074-BAEE-F921A8EE63B4Q34715598-903A669F-90DA-4783-A9A5-038622DBC266Q35800825-0BF28546-3CD2-4A36-B3AA-7308C2B7FF30Q37366202-09CFA57E-F45C-4F9C-A388-067539FECA24Q37615574-04A8038C-75EF-4872-A4AE-F57A7C20C2FEQ38241761-6A581D3E-B56E-4D51-B151-2B71E2941DC3Q38285621-4B77E98E-7902-45A2-B7E2-A1BBCB46FEBAQ38664735-5C026711-1B70-4F43-85E2-1B2CA207E647Q38735991-AE18BD76-46A7-4BE2-AFFE-44FB71D0809EQ38753586-FEF56C96-7F28-4E14-AB63-45E49C61445DQ38756932-D1FA3018-AB0B-4B10-99AE-2A8B759F7C0AQ38760822-45A79031-A360-4C43-B6EE-E08FB89F742AQ38783162-FD6E9B60-4FCA-4785-961D-D4A5B062464FQ38785380-9A359928-EE7C-4D9C-8A8B-66325D869231Q38835119-24EA2C0E-9387-4DCB-BE9D-E861CBE9F8EEQ38845834-E00B3D41-06E1-478C-9325-AD84D85102FBQ38885249-032AB7F2-4500-4246-8E3C-9FA22748366BQ39112940-159A2DA8-6EAE-42B8-9099-3DCC7550F9C4Q53817434-46B57E99-9A20-4BB4-BD19-B0EBB1E8366BQ54303287-EECC3D2C-2688-4685-AB10-7A7B30C1BC54
P2860
Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 June 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Phase I study assessing the sa ...... e in elderly patients with AML
@en
Phase I study assessing the safety and tolerability of barasertib
@nl
type
label
Phase I study assessing the sa ...... e in elderly patients with AML
@en
Phase I study assessing the safety and tolerability of barasertib
@nl
prefLabel
Phase I study assessing the sa ...... e in elderly patients with AML
@en
Phase I study assessing the safety and tolerability of barasertib
@nl
P2093
P2860
P1476
Phase I study assessing the sa ...... e in elderly patients with AML
@en
P2093
Elias J Jabbour
Mikkael A Sekeres
Paul K Stockman
Philippe Rousselot
Stuart D Oliver
Vincent Ribrag
P2860
P304
P356
10.1016/J.CLML.2013.03.019
P407
P577
2013-06-10T00:00:00Z